Tag: Idarucizumab
Boehringer Ingelheim launches RE-VECTO global programme to explore idarucizumab use in...
Boehringer Ingelheim has announced the launch of its global RE-VECTO programme for idarucizumab (Praxbind), the specific reversal agent for dabigatran etexilate (Pradaxa).
Idarucizumab is approved...
Idarucizumab licensed in Europe as specific reversal agent of dabigatran
Boehringer Ingelheim has announced that the European Commission has licensed idarucizumab (Praxbind) for rapid and specific reversal of the anticoagulant effects of dabigatran etexilate in cases of emergency surgery/urgent procedures or in situations of life-threatening or uncontrolled bleeding.